Table 5. Outcomes from univariate regression analysis of the genomic markers.
| Variable | Unit | Variable type | P value Wald* | P value likelihood ratio * | HR* | 95% CI* |
|---|---|---|---|---|---|---|
| CEP7 gain | % | continuous | 0.02 | 0.0179 | 1.22 | (1.03–1.43) |
| c-MYC gain | % | continuous | 0.2 | 0.206 | 1.12 | (0.94–1.33) |
| CEP17 gain | % | continuous | 0.4 | 0.395 | 1.05 | (0.94–1.16) |
| CEP17 loss | % | continuous | 0.5 | 0.466 | 0.91 | (0.70–1.18) |
| 20q gain | % | continuous | 0.5 | 0.469 | 1.08 | (0.87–1.34) |
| CEP7 loss | % | continuous | 0.5 | 0.475 | 1.06 | (0.91–1.23) |
| Aneusomy | % | continuous | 0.5 | 0.497 | 1.02 | (0.96–1.09) |
| ERBB2 gain | % | continuous | 0.7 | 0.729 | 1.02 | (0.91–1.15) |
| CDKN2A loss | % | continuous | 0.7 | 0.689 | 0.99 | (0.94–1.04) |
| TP53 loss | % | continuous | 0.9 | 0.941 | 1 | (0.88–1.3) |
* Results from univariate Cox proportional hazards models. Bold values indicate statistical significance (P<0.05).
HR, Hazard Ratio; CI, Confidence Interval.